Product Description
The DV2-96 monoclonal antibody reacts with sites along the lateral ridge of the DIII domain on the E protein of dengue virus serotype 2 (DENV-2). Dengue virus (DENV) is a single-stranded RNA virus that causes dengue fever and is transmitted to humans by infected female mosquitoes (Aedes aegypti). DENV infections have emerged as a global health problem in the tropics and subtropics, risking almost 50% of the worlds population. DENV has four genetically related but antigenically distinct serotypes, namely DENV-1, DENV-2, DENV-3, and DENV-4. After infection, the DENV virus particles stay viable and replicate within RBCs, platelets, and hemopoietic cells. According to scientific research, depending on pre-existing antibodies and the following infecting serotype, a DENV infection can either protect against or increase the severity of a subsequent dengue infection, e.g., DENV-2. Experimental studies have shown that a larger neutralizing antibody titer is required to protect against symptomatic DENV-2 than other serotypes, and a wide range of pre-existing anti-DENV-binding antibody titers can exacerbate DENV-2 symptoms and sickness. All DENV serotypes are neurotropic, but DENV-2 causes severe to potentially fatal deterioration of the CNS, and DENV-2 is the most frequent cause of dengue epidemics worldwide. Experimental research involving BHK21 cell-based PRNT assays demonstrated the in vitro neutralizing activity of the DV2-96 monoclonal antibody against multiple DENV-2 genotypes, such as 16681, Southeast Asian, NGC, Southeast Asian, C0477, Southeast Asian, ArA6894, Indian, IQT2913, American, and PM33974, West African. Notably, in antibody-dependent enhancement (ADE) assays using P388D1 cells, in vitro incubation of a range of concentrations of DV2-96 monoclonal antibody with immature DENV (prior to infection) promoted the infectivity of immature DENV particles through its ADE effects. In prophylactic experiments with BALB/c mice, a single in vivo dose of the DV2-96 monoclonal antibody (500 µg/mouse) one day prior to an intracranial infection with DENV-2 NGC provided significant protection against the lethal infection of DENV-2 NGC. Post-infection therapeutic experiments also demonstrated the in vivo protective efficacy of the DV2-96 monoclonal antibody against DENV-2 NGC infection in mice.
* VAT and shipping costs not included. Errors and price changes excepted
